Global Xerostomia Treatments Market
Global Xerostomia Treatments Market

Xerostomia Treatments Comprehensive Study by Type (OTC, Prescription), Application (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), Treatment Type (Artificial Saliva, Salivary Stimulants, Saliva Substitutes, Drugs, Salivary Pens, Others), Symptoms (Sjogrenís Syndrome, Cancer, Others) Players and Region - Global Market Outlook to 2025

Xerostomia Treatments Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Aug 2020 Edition 241 Pages 184 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Xerostomia Treatments Market Overview:
Xerostomia is a condition that leads to the dry mouth caused by the minimal amount or absence of saliva in the mouth. Xerostomia is not viewed as a disease, but rather as a symptom. Xerostomia can be caused by radiation to the head or neck, or as a side effect of medications. In addition to the underlying disease as the cause, there are other causes for this condition. These include inadequate fluid consumption, sleeping with your mouth open, and weather conditions. The decreasing function of the salivary gland may or may not cause xerostomia to develop. This condition is most common in the elderly due to the frequent use of medication. It affects around 20% of the elderly worldwide. Xerostomia is associated with difficulty eating, speaking, swallowing, and wearing dentures. A dew patient suffering from this disease also suffers from dysgeusia, glossodynia, and other dental complications. To determine the function of the salivary gland, various diagnostic and imaging tests such as sialometry, salivary flow measurement, and sialography are recommended. If the salivary flow rate is less than 0.1 ml/minute, the condition is considered xerostomia.

Market Drivers
  • Increasing Adoption of Chemotherapy and Radiotherapy in Cancer Treatment
  • The Rising Use of Prescribed Medications
  • Rising Consumption of Medications
  • Favorable Reimbursement Policies

Market Trend
  • Growing Geriatric Population Including Aging Baby Boomers
  • Easy Availability of Cost-Effective Medications
  • Increasing Prevalence of Diseases Such As Parkinsonís disease, Hypertension, Diabetes, And HIV

Restraints
  • Scarcity of Skilled Professionals to Avail the Proper Treatment Options
  • Availability of a Wide Range of Substitutes

Opportunities
  • Growing Awareness and Supporting Patients with Xerostomia
  • Growing Healthcare Expenditure and Availability of Advanced Health Care Facilities

Challenges
  • The Lack of Awareness among the People


Competitive Landscape:
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are GlaxoSmithKline (United Kingdom), Church and Dwight Co., Inc. (United States), Hikma Pharmaceuticals (United Kingdom), Pendopharm (Canada), Parnell Pharmaceuticals, Inc. (Australia), Orahealth Corporation (United States), Eisai Co., Ltd (Japan), EUSA Pharma (United Kingdom), Colgate-Palmolive Company (United States), Forward Science (United States), Mission Pharmacal Company (United States) and OraPharma, Inc. (United States). Additionally, following companies can also be profiled that are part of our coverage like Saliwell Ltd. (Israel) and Sun Pharmaceutical Industries Limited (India). Analyst at AdvanceMarketAnalytics see United States Players to retain maximum share of Global Xerostomia Treatments market by 2025. Considering Market by Treatment Type, the sub-segment i.e. Artificial Saliva will boost the Xerostomia Treatments market. Considering Market by Symptoms, the sub-segment i.e. Sjogrenís Syndrome will boost the Xerostomia Treatments market.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Xerostomia Treatments market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Xerostomia Treatments market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Providers of Xerostomia Treatments, Research Institute, Potential Investors, Hospitals Sectors, Government Sector and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • OTC
  • Prescription
By Application
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
By Treatment Type
  • Artificial Saliva
  • Salivary Stimulants
  • Saliva Substitutes
  • Drugs
  • Salivary Pens
  • Others

By Symptoms
  • Sjogrenís Syndrome
  • Cancer
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Adoption of Chemotherapy and Radiotherapy in Cancer Treatment
      • 3.2.2. The Rising Use of Prescribed Medications
      • 3.2.3. Rising Consumption of Medications
      • 3.2.4. Favorable Reimbursement Policies
    • 3.3. Market Challenges
      • 3.3.1. The Lack of Awareness among the People
    • 3.4. Market Trends
      • 3.4.1. Growing Geriatric Population Including Aging Baby Boomers
      • 3.4.2. Easy Availability of Cost-Effective Medications
      • 3.4.3. Increasing Prevalence of Diseases Such As Parkinsonís disease, Hypertension, Diabetes, And HIV
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Xerostomia Treatments, by Type, Application, Treatment Type, Symptoms and Region (value and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Xerostomia Treatments (Value)
      • 5.2.1. Global Xerostomia Treatments by: Type (Value)
        • 5.2.1.1. OTC
        • 5.2.1.2. Prescription
      • 5.2.2. Global Xerostomia Treatments by: Application (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Online Pharmacies
        • 5.2.2.3. Retail Pharmacies
      • 5.2.3. Global Xerostomia Treatments by: Treatment Type (Value)
        • 5.2.3.1. Artificial Saliva
        • 5.2.3.2. Salivary Stimulants
        • 5.2.3.3. Saliva Substitutes
        • 5.2.3.4. Drugs
        • 5.2.3.5. Salivary Pens
        • 5.2.3.6. Others
      • 5.2.4. Global Xerostomia Treatments by: Symptoms (Value)
        • 5.2.4.1. Sjogrenís Syndrome
        • 5.2.4.2. Cancer
        • 5.2.4.3. Others
      • 5.2.5. Global Xerostomia Treatments Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Xerostomia Treatments (Price)
      • 5.3.1. Global Xerostomia Treatments by: Type (Price)
  • 6. Xerostomia Treatments: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Church and Dwight Co., Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Hikma Pharmaceuticals (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pendopharm (Canada)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Parnell Pharmaceuticals, Inc. (Australia)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Orahealth Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Eisai Co., Ltd (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. EUSA Pharma (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Colgate-Palmolive Company (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Forward Science (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Mission Pharmacal Company (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. OraPharma, Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Xerostomia Treatments Sale, by Type, Application, Treatment Type, Symptoms and Region (value and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Xerostomia Treatments (Value)
      • 7.2.1. Global Xerostomia Treatments by: Type (Value)
        • 7.2.1.1. OTC
        • 7.2.1.2. Prescription
      • 7.2.2. Global Xerostomia Treatments by: Application (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Online Pharmacies
        • 7.2.2.3. Retail Pharmacies
      • 7.2.3. Global Xerostomia Treatments by: Treatment Type (Value)
        • 7.2.3.1. Artificial Saliva
        • 7.2.3.2. Salivary Stimulants
        • 7.2.3.3. Saliva Substitutes
        • 7.2.3.4. Drugs
        • 7.2.3.5. Salivary Pens
        • 7.2.3.6. Others
      • 7.2.4. Global Xerostomia Treatments by: Symptoms (Value)
        • 7.2.4.1. Sjogrenís Syndrome
        • 7.2.4.2. Cancer
        • 7.2.4.3. Others
      • 7.2.5. Global Xerostomia Treatments Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Xerostomia Treatments (Price)
      • 7.3.1. Global Xerostomia Treatments by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Xerostomia Treatments: by Type(USD Million)
  • Table 2. Xerostomia Treatments OTC , by Region USD Million (2014-2019)
  • Table 3. Xerostomia Treatments Prescription , by Region USD Million (2014-2019)
  • Table 4. Xerostomia Treatments: by Application(USD Million)
  • Table 5. Xerostomia Treatments Hospital Pharmacies , by Region USD Million (2014-2019)
  • Table 6. Xerostomia Treatments Online Pharmacies , by Region USD Million (2014-2019)
  • Table 7. Xerostomia Treatments Retail Pharmacies , by Region USD Million (2014-2019)
  • Table 8. Xerostomia Treatments: by Treatment Type(USD Million)
  • Table 9. Xerostomia Treatments Artificial Saliva , by Region USD Million (2014-2019)
  • Table 10. Xerostomia Treatments Salivary Stimulants , by Region USD Million (2014-2019)
  • Table 11. Xerostomia Treatments Saliva Substitutes , by Region USD Million (2014-2019)
  • Table 12. Xerostomia Treatments Drugs , by Region USD Million (2014-2019)
  • Table 13. Xerostomia Treatments Salivary Pens , by Region USD Million (2014-2019)
  • Table 14. Xerostomia Treatments Others , by Region USD Million (2014-2019)
  • Table 15. Xerostomia Treatments: by Symptoms(USD Million)
  • Table 16. Xerostomia Treatments Sjogrenís Syndrome , by Region USD Million (2014-2019)
  • Table 17. Xerostomia Treatments Cancer , by Region USD Million (2014-2019)
  • Table 18. Xerostomia Treatments Others , by Region USD Million (2014-2019)
  • Table 19. South America Xerostomia Treatments, by Country USD Million (2014-2019)
  • Table 20. South America Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 21. South America Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 22. South America Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 23. South America Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 24. Brazil Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 25. Brazil Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 26. Brazil Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 27. Brazil Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 28. Argentina Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 29. Argentina Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 30. Argentina Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 31. Argentina Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 32. Rest of South America Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 33. Rest of South America Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 34. Rest of South America Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 35. Rest of South America Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 36. Asia Pacific Xerostomia Treatments, by Country USD Million (2014-2019)
  • Table 37. Asia Pacific Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 38. Asia Pacific Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 39. Asia Pacific Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 40. Asia Pacific Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 41. China Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 42. China Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 43. China Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 44. China Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 45. Japan Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 46. Japan Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 47. Japan Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 48. Japan Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 49. India Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 50. India Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 51. India Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 52. India Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 53. South Korea Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 54. South Korea Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 55. South Korea Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 56. South Korea Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 57. Taiwan Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 58. Taiwan Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 59. Taiwan Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 60. Taiwan Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 61. Australia Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 62. Australia Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 63. Australia Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 64. Australia Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 65. Rest of Asia-Pacific Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 66. Rest of Asia-Pacific Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 67. Rest of Asia-Pacific Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 68. Rest of Asia-Pacific Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 69. Europe Xerostomia Treatments, by Country USD Million (2014-2019)
  • Table 70. Europe Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 71. Europe Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 72. Europe Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 73. Europe Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 74. Germany Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 75. Germany Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 76. Germany Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 77. Germany Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 78. France Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 79. France Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 80. France Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 81. France Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 82. Italy Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 83. Italy Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 84. Italy Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 85. Italy Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 86. United Kingdom Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 87. United Kingdom Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 88. United Kingdom Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 89. United Kingdom Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 90. Netherlands Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 91. Netherlands Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 92. Netherlands Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 93. Netherlands Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 94. Rest of Europe Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 95. Rest of Europe Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 96. Rest of Europe Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 97. Rest of Europe Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 98. MEA Xerostomia Treatments, by Country USD Million (2014-2019)
  • Table 99. MEA Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 100. MEA Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 101. MEA Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 102. MEA Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 103. Middle East Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 104. Middle East Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 105. Middle East Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 106. Middle East Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 107. Africa Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 108. Africa Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 109. Africa Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 110. Africa Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 111. North America Xerostomia Treatments, by Country USD Million (2014-2019)
  • Table 112. North America Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 113. North America Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 114. North America Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 115. North America Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 116. United States Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 117. United States Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 118. United States Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 119. United States Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 120. Canada Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 121. Canada Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 122. Canada Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 123. Canada Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 124. Mexico Xerostomia Treatments, by Type USD Million (2014-2019)
  • Table 125. Mexico Xerostomia Treatments, by Application USD Million (2014-2019)
  • Table 126. Mexico Xerostomia Treatments, by Treatment Type USD Million (2014-2019)
  • Table 127. Mexico Xerostomia Treatments, by Symptoms USD Million (2014-2019)
  • Table 128. Xerostomia Treatments: by Type(USD/Units)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Xerostomia Treatments: by Type(USD Million)
  • Table 142. Xerostomia Treatments OTC , by Region USD Million (2020-2025)
  • Table 143. Xerostomia Treatments Prescription , by Region USD Million (2020-2025)
  • Table 144. Xerostomia Treatments: by Application(USD Million)
  • Table 145. Xerostomia Treatments Hospital Pharmacies , by Region USD Million (2020-2025)
  • Table 146. Xerostomia Treatments Online Pharmacies , by Region USD Million (2020-2025)
  • Table 147. Xerostomia Treatments Retail Pharmacies , by Region USD Million (2020-2025)
  • Table 148. Xerostomia Treatments: by Treatment Type(USD Million)
  • Table 149. Xerostomia Treatments Artificial Saliva , by Region USD Million (2020-2025)
  • Table 150. Xerostomia Treatments Salivary Stimulants , by Region USD Million (2020-2025)
  • Table 151. Xerostomia Treatments Saliva Substitutes , by Region USD Million (2020-2025)
  • Table 152. Xerostomia Treatments Drugs , by Region USD Million (2020-2025)
  • Table 153. Xerostomia Treatments Salivary Pens , by Region USD Million (2020-2025)
  • Table 154. Xerostomia Treatments Others , by Region USD Million (2020-2025)
  • Table 155. Xerostomia Treatments: by Symptoms(USD Million)
  • Table 156. Xerostomia Treatments Sjogrenís Syndrome , by Region USD Million (2020-2025)
  • Table 157. Xerostomia Treatments Cancer , by Region USD Million (2020-2025)
  • Table 158. Xerostomia Treatments Others , by Region USD Million (2020-2025)
  • Table 159. South America Xerostomia Treatments, by Country USD Million (2020-2025)
  • Table 160. South America Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 161. South America Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 162. South America Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 163. South America Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 164. Brazil Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 165. Brazil Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 166. Brazil Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 167. Brazil Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 168. Argentina Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 169. Argentina Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 170. Argentina Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 171. Argentina Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 172. Rest of South America Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 173. Rest of South America Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 174. Rest of South America Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 175. Rest of South America Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 176. Asia Pacific Xerostomia Treatments, by Country USD Million (2020-2025)
  • Table 177. Asia Pacific Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 178. Asia Pacific Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 179. Asia Pacific Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 180. Asia Pacific Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 181. China Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 182. China Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 183. China Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 184. China Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 185. Japan Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 186. Japan Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 187. Japan Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 188. Japan Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 189. India Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 190. India Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 191. India Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 192. India Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 193. South Korea Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 194. South Korea Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 195. South Korea Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 196. South Korea Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 197. Taiwan Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 198. Taiwan Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 199. Taiwan Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 200. Taiwan Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 201. Australia Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 202. Australia Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 203. Australia Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 204. Australia Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 205. Rest of Asia-Pacific Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 206. Rest of Asia-Pacific Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 207. Rest of Asia-Pacific Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 208. Rest of Asia-Pacific Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 209. Europe Xerostomia Treatments, by Country USD Million (2020-2025)
  • Table 210. Europe Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 211. Europe Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 212. Europe Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 213. Europe Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 214. Germany Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 215. Germany Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 216. Germany Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 217. Germany Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 218. France Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 219. France Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 220. France Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 221. France Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 222. Italy Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 223. Italy Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 224. Italy Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 225. Italy Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 226. United Kingdom Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 227. United Kingdom Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 228. United Kingdom Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 229. United Kingdom Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 230. Netherlands Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 231. Netherlands Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 232. Netherlands Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 233. Netherlands Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 234. Rest of Europe Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 235. Rest of Europe Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 236. Rest of Europe Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 237. Rest of Europe Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 238. MEA Xerostomia Treatments, by Country USD Million (2020-2025)
  • Table 239. MEA Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 240. MEA Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 241. MEA Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 242. MEA Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 243. Middle East Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 244. Middle East Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 245. Middle East Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 246. Middle East Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 247. Africa Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 248. Africa Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 249. Africa Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 250. Africa Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 251. North America Xerostomia Treatments, by Country USD Million (2020-2025)
  • Table 252. North America Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 253. North America Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 254. North America Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 255. North America Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 256. United States Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 257. United States Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 258. United States Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 259. United States Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 260. Canada Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 261. Canada Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 262. Canada Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 263. Canada Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 264. Mexico Xerostomia Treatments, by Type USD Million (2020-2025)
  • Table 265. Mexico Xerostomia Treatments, by Application USD Million (2020-2025)
  • Table 266. Mexico Xerostomia Treatments, by Treatment Type USD Million (2020-2025)
  • Table 267. Mexico Xerostomia Treatments, by Symptoms USD Million (2020-2025)
  • Table 268. Xerostomia Treatments: by Type(USD/Units)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Xerostomia Treatments: by Type USD Million (2014-2019)
  • Figure 5. Global Xerostomia Treatments: by Application USD Million (2014-2019)
  • Figure 6. Global Xerostomia Treatments: by Treatment Type USD Million (2014-2019)
  • Figure 7. Global Xerostomia Treatments: by Symptoms USD Million (2014-2019)
  • Figure 8. South America Xerostomia Treatments Share (%), by Country
  • Figure 9. Asia Pacific Xerostomia Treatments Share (%), by Country
  • Figure 10. Europe Xerostomia Treatments Share (%), by Country
  • Figure 11. MEA Xerostomia Treatments Share (%), by Country
  • Figure 12. North America Xerostomia Treatments Share (%), by Country
  • Figure 13. Global Xerostomia Treatments: by Type USD/Units (2014-2019)
  • Figure 14. Global Xerostomia Treatments share by Players 2019 (%)
  • Figure 15. Global Xerostomia Treatments share by Players (Top 3) 2019(%)
  • Figure 16. Global Xerostomia Treatments share by Players (Top 5) 2019(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2019
  • Figure 20. Church and Dwight Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Church and Dwight Co., Inc. (United States) Revenue: by Geography 2019
  • Figure 22. Hikma Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. Hikma Pharmaceuticals (United Kingdom) Revenue: by Geography 2019
  • Figure 24. Pendopharm (Canada) Revenue, Net Income and Gross profit
  • Figure 25. Pendopharm (Canada) Revenue: by Geography 2019
  • Figure 26. Parnell Pharmaceuticals, Inc. (Australia) Revenue, Net Income and Gross profit
  • Figure 27. Parnell Pharmaceuticals, Inc. (Australia) Revenue: by Geography 2019
  • Figure 28. Orahealth Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 29. Orahealth Corporation (United States) Revenue: by Geography 2019
  • Figure 30. Eisai Co., Ltd (Japan) Revenue, Net Income and Gross profit
  • Figure 31. Eisai Co., Ltd (Japan) Revenue: by Geography 2019
  • Figure 32. EUSA Pharma (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. EUSA Pharma (United Kingdom) Revenue: by Geography 2019
  • Figure 34. Colgate-Palmolive Company (United States) Revenue, Net Income and Gross profit
  • Figure 35. Colgate-Palmolive Company (United States) Revenue: by Geography 2019
  • Figure 36. Forward Science (United States) Revenue, Net Income and Gross profit
  • Figure 37. Forward Science (United States) Revenue: by Geography 2019
  • Figure 38. Mission Pharmacal Company (United States) Revenue, Net Income and Gross profit
  • Figure 39. Mission Pharmacal Company (United States) Revenue: by Geography 2019
  • Figure 40. OraPharma, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 41. OraPharma, Inc. (United States) Revenue: by Geography 2019
  • Figure 42. Global Xerostomia Treatments: by Type USD Million (2020-2025)
  • Figure 43. Global Xerostomia Treatments: by Application USD Million (2020-2025)
  • Figure 44. Global Xerostomia Treatments: by Treatment Type USD Million (2020-2025)
  • Figure 45. Global Xerostomia Treatments: by Symptoms USD Million (2020-2025)
  • Figure 46. South America Xerostomia Treatments Share (%), by Country
  • Figure 47. Asia Pacific Xerostomia Treatments Share (%), by Country
  • Figure 48. Europe Xerostomia Treatments Share (%), by Country
  • Figure 49. MEA Xerostomia Treatments Share (%), by Country
  • Figure 50. North America Xerostomia Treatments Share (%), by Country
  • Figure 51. Global Xerostomia Treatments: by Type USD/Units (2020-2025)
Some of the key companies/manufacturers profiled in the report
  • GlaxoSmithKline (United Kingdom)
  • Church and Dwight Co., Inc. (United States)
  • Hikma Pharmaceuticals (United Kingdom)
  • Pendopharm (Canada)
  • Parnell Pharmaceuticals, Inc. (Australia)
  • Orahealth Corporation (United States)
  • Eisai Co., Ltd (Japan)
  • EUSA Pharma (United Kingdom)
  • Colgate-Palmolive Company (United States)
  • Forward Science (United States)
  • Mission Pharmacal Company (United States)
  • OraPharma, Inc. (United States)
Additional players considered in the study are as follows:
Saliwell Ltd. (Israel) , Sun Pharmaceutical Industries Limited (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation